We expect investors to focus on Compugen Ltd.’s CGEN progress with the development of its portfolio of pipeline candidates for various oncology indications, when it reports third-quarter 2024 earnings...
Source LinkWe expect investors to focus on Compugen Ltd.’s CGEN progress with the development of its portfolio of pipeline candidates for various oncology indications, when it reports third-quarter 2024 earnings...
Source Link
Comments